Daniel Scott Allison

US Patent:

8609818, Dec 17, 2013

Filed:

Mar 9, 2012

Appl. No.:

13/416752

Inventors:

John Benjamin Leppard - Mukilteo WA, US
Christi L Wood - Snohomish WA, US
W Jason Cummings - Bellevue WA, US
Munehisa Yabuki - Seattle WA, US
Nancy Maizels - Seattle WA, US
Daniel S Allison - Lake Forest Park WA, US
Larry W Tjoelker - Kirkland WA, US

Assignee:

Omeros Corporation - Seattle WA

International Classification:

C07K 16/00
C07K 16/46
C07K 16/28

US Classification:

5303871, 5303873, 53038822, 5303911, 5303917

Abstract:

The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.

US Patent:

20060121574, Jun 8, 2006

Filed:

Dec 8, 2005

Appl. No.:

11/298020

Inventors:

Daniel Allison - Seattle WA, US

Assignee:

ICOS CORPORATION - Bothell WA

International Classification:

C12P 21/06
C07H 21/04
C12N 5/06
C07K 16/18

US Classification:

435069100, 435070210, 435326000, 435320100, 530388100, 536023530

Abstract:

The present invention relates to methods for making multimeric proteins comprising fusion of two or more cells expressing a single subunit of the multimeric protein to generate a single hybrid cell expressing the fully assembled multimeric protein.

US Patent:

20080293105, Nov 27, 2008

Filed:

May 14, 2007

Appl. No.:

11/803356

Inventors:

Daniel S. Allison - Seattle WA, US

Assignee:

ICOS CORPORATION - Bothell WA

International Classification:

C12P 21/04

US Classification:

435 696, 435 691

Abstract:

The present invention relates to methods for making multimeric proteins comprising fusion of two or more cells expressing a single subunit of the multimeric protein to generate a single hybrid cell expressing the fully assembled multimeric protein.

US Patent:

20130095104, Apr 18, 2013

Filed:

Aug 9, 2012

Appl. No.:

13/571151

Inventors:

W. Jason Cummings - Bellevue WA, US
Munehisa Yabuki - Seattle WA, US
John B. Leppard - Mukilteo WA, US
Christi L. Wood - Snohomish WA, US
Nancy Maizels - Seattle WA, US
Daniel S. Allison - Lake Forest Park WA, US
Larry W. Tjoelker - Kirkland WA, US

International Classification:

C07K 16/28

US Classification:

4241351, 5303879, 5303873, 5303917, 4241391, 435375, 4241331, 4241781

Abstract:

The present invention relates generally to anti-FZD10 antibodies and to methods of using anti-FZD10 antibodies. In particular, the anti-FZD10 antibodies described herein are useful for altering one or more of survival, replication, differentiation and epithelial-to-mesenchymal cell transition of embryonic stem cells and/or for the treatment of diseases, such as a variety of cancers, associated with expression of FZD10, including as stand-alone therapies and in combination therapies with other agents.

US Patent:

58888098, Mar 30, 1999

Filed:

May 1, 1997

Appl. No.:

8/847218

Inventors:

Daniel S. Allison - Seattle WA

Assignee:

ICOS Corporation - Bothell WA

International Classification:

C12N 510
C12N 100
C12N 1511
C12N 1563

US Classification:

435325

Abstract:

The present invention relates to regulatory DNA sequences derived from the hamster EF-1. alpha. gene. The invention further encompasses expression constructs comprising regulatory DNA of the invention, host cells transformed or transfected with the regulatory DNA and methods of increasing gene transcription utilizing the regulatory DNA. Expression constructs comprising regulatory DNA of the invention operably linked to specific gene sequences are also comprehended.

US Patent:

20220306734, Sep 29, 2022

Filed:

Jul 22, 2020

Appl. No.:

17/629213

Inventors:

- Valby, DK
Leon F. GARCIA-MARTINEZ - Woodinville WA, US
Benjamin H. DUTZAR - Seattle WA, US
Daniel S. ALLISON - Forest Park WA, US
Jens BILLGREN - Seattle WA, US
Michelle SCALLEY-KIM - Seattle WA, US
Ethan Wayne OJALA - Snohomish WA, US
Jenny MULLIGAN - Lake Forest Park WA, US
Pei FAN - Bothell WA, US
Maria-Cristina LOOMIS - Bothell WA, US
Jeffrey T.L. SMITH - Dublin, IE
John A. LATHAM - Seattle WA, US
Vanessa Lisbeth RUBIN - Seattle WA, US

International Classification:

C07K 16/28
A61P 1/04
A61P 13/10
A61P 25/06

Abstract:

This invention generally pertains to antibodies and antigen-binding antibody Fragments, preferably humanized, chimeric, and human antibodies and antigen-binding antibody fragments. compositions containing such antibodies and antigen-binding antibody fragments or cells, e.g., immune cells such as T, Treg, or NK cells which express same, wherein such antibodies and antigen-binding antibody Fragments specifically bind to mGluR5. The invention also relates to therapeutic and diagnostic uses for the antibodies, antigen-binding antibody fragments, and compositions thereof.

US Patent:

20220289836, Sep 15, 2022

Filed:

Dec 16, 2021

Appl. No.:

17/553280

Inventors:

- VALBY, DK
Leon F. GARCIA-MARTINEZ - Woodinville WA, US
Benjamin H. DUTZAR - Seattle WA, US
Daniel S. ALLISON - Lake Forest Park WA, US
Katherine Lee HENDRIX - Renton WA, US
Ethan W. OJALA - Snohomish WA, US
Pei FAN - Bothell WA, US
Jeffrey T.L. SMITH - Bellevue WA, US
John A. LATHAM - Seattle WA, US
Charlie KARASEK - Seattle WA, US
Jenny MULLIGAN - Lake Forest Park WA, US
Michelle SCALLEY-KIM - Seattle WA, US
Erica STEWART - Seattle WA, US
Vanessa Lisbeth RUBIN - Seattle WA, US
Jens J. BILLGREN - Bothell WA, US

International Classification:

C07K 16/26
A61K 39/395

Abstract:

The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific V, V, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.

US Patent:

20230125604, Apr 27, 2023

Filed:

Apr 19, 2022

Appl. No.:

17/723674

Inventors:

- Valby, DK
Leon Garcia-Martinez - Woodinville WA, US
Benjamin H. Dutzar - Seattle WA, US
Daniel S. Allison - Lake Forest Park WA, US
Katherine Lee Hendrix - Bothell WA, US
Ethan W. Ojala - Snohomish WA, US
Pei Fan - Bothell WA, US
Jeffrey T.L. Smith - Dublin, IE
John A. Latham - Seattle WA, US
Charlie Karasek - Seattle WA, US
Jenny Mulligan - Lake Forest Park WA, US
Michelle Scalley-Kim - Seattle WA, US
Erica Stewart - Seattle WA, US
Vanessa Lisbeth Rubin - Seattle WA, US
Jens J. Billgren - Seattle WA, US

International Classification:

C07K 14/705
C12N 15/09
C12N 15/63
A61K 39/395
C07K 16/28
A61K 38/17
A61K 38/22
C07K 14/47
C07K 14/72
C07K 16/18
C12N 5/07
C07K 16/26
C07K 16/42
G01N 33/68

Abstract:

The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V, V, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.